Free Trial
→ The Iran War Isn’t Chaos. It’s Strategy. (From Behind the Markets) (Ad)tc pixel Free HBP Stock Alerts

Helix BioPharma (HBP) Competitors

Helix BioPharma logo
C$0.96 0.00 (0.00%)
As of 10/13/2026 03:46 PM Eastern
Compare

HBP vs. ABCN, TH, BCT, COV, and SCYB

Should you buy Helix BioPharma stock or one of its competitors? Helix BioPharma's main competitors and comparable companies include VIVO Cannabis (ABCN), Theratechnologies (TH), BriaCell Therapeutics (BCT), Covalon Technologies (COV), and Scythian Biosciences (SCYB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Helix BioPharma compare to VIVO Cannabis?

VIVO Cannabis (CVE:ABCN) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

VIVO Cannabis' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
VIVO CannabisN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVO CannabisN/AN/AN/AN/AN/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, Helix BioPharma had 1 more articles in the media than VIVO Cannabis. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for VIVO Cannabis. VIVO Cannabis' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
VIVO Cannabis Neutral
Helix BioPharma Neutral

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Helix BioPharma beats VIVO Cannabis on 3 of the 5 factors compared between the two stocks.

How does Helix BioPharma compare to Theratechnologies?

Helix BioPharma (TSE:HBP) and Theratechnologies (TSE:TH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Theratechnologies has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
TheratechnologiesC$84.38M2.44-C$1.96M-C$0.19N/A

In the previous week, Helix BioPharma had 1 more articles in the media than Theratechnologies. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Theratechnologies. Helix BioPharma's average media sentiment score of 0.00 equaled Theratechnologies'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
Theratechnologies Neutral

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.5% of Theratechnologies shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Comparatively, 1.2% of Theratechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Helix BioPharma has a beta of 1.154669, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Theratechnologies has a beta of 0.256166, suggesting that its share price is 74% less volatile than the broader market.

Helix BioPharma has a net margin of 0.00% compared to Theratechnologies' net margin of -9.67%. Theratechnologies' return on equity of 36.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Theratechnologies -9.67%36.00%5.15%

Summary

Theratechnologies beats Helix BioPharma on 6 of the 11 factors compared between the two stocks.

How does Helix BioPharma compare to BriaCell Therapeutics?

Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (CVE:BCT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
BriaCell TherapeuticsN/AN/AN/A-C$0.38N/A

In the previous week, Helix BioPharma had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for BriaCell Therapeutics. Helix BioPharma's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
BriaCell Therapeutics Neutral

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BriaCell Therapeutics' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
BriaCell Therapeutics N/A N/A N/A

Summary

Helix BioPharma beats BriaCell Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Helix BioPharma compare to Covalon Technologies?

Helix BioPharma (TSE:HBP) and Covalon Technologies (CVE:COV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, Helix BioPharma had 1 more articles in the media than Covalon Technologies. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Covalon Technologies. Helix BioPharma's average media sentiment score of 0.00 equaled Covalon Technologies'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
Covalon Technologies Neutral

Covalon Technologies has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
Covalon TechnologiesC$34.35M3.27C$2.39MC$0.1625.44

0.0% of Helix BioPharma shares are held by institutional investors. Comparatively, 0.2% of Covalon Technologies shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by company insiders. Comparatively, 48.7% of Covalon Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Helix BioPharma has a beta of 1.154669, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Covalon Technologies has a beta of 0.939041, meaning that its stock price is 6% less volatile than the broader market.

Covalon Technologies has a net margin of 12.78% compared to Helix BioPharma's net margin of 0.00%. Covalon Technologies' return on equity of 15.04% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Covalon Technologies 12.78%15.04%-3.25%

Summary

Covalon Technologies beats Helix BioPharma on 9 of the 11 factors compared between the two stocks.

How does Helix BioPharma compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Scythian Biosciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Scythian BiosciencesN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scythian BiosciencesN/AN/AN/AN/AN/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Helix BioPharma had 1 more articles in the media than Scythian Biosciences. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Scythian Biosciences. Scythian Biosciences' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
Scythian Biosciences Neutral
Helix BioPharma Neutral

Summary

Helix BioPharma beats Scythian Biosciences on 3 of the 5 factors compared between the two stocks.

Get Helix BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HBP vs. The Competition

Export
MetricHelix BioPharmaBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$73.32MC$3.93BC$7.26BC$12.72B
Dividend Yield1.50%3.65%2.52%6.34%
P/E Ratio-24.0011.31206.6638.35
Price / SalesN/A1,148.46562.218.68
Price / Cash11.32118.5077.1682.29
Price / Book4.9917.0810.754.44
Net Income-C$50.55M-C$22.69MC$3.50BC$299.09M
7 Day Performance6.67%-4.43%-2.91%0.69%
1 Month Performance-31.43%-12.48%-7.38%-1.38%
1 Year Performance-65.09%7.60%2.96%15.18%

Helix BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
N/AC$0.96
flat		N/A-60.0%C$73.32MN/AN/A9
ABCN
VIVO Cannabis
N/AC$1.32
+5.6%		N/A+0.0%C$256.62MN/AN/AN/A
TH
Theratechnologies
N/AC$4.47
-4.9%		N/A+0.0%C$205.53MC$84.38MN/A103
BCT
BriaCell Therapeutics
N/AC$10.60
-3.8%		N/A+0.0%C$168.68MN/AN/A5
COV
Covalon Technologies
N/AC$4.05
-6.7%		N/A+102.5%C$111.85MC$34.35M25.31105

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HBP) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...
Behind the Markets | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
How one AI fund pays investors every Thursday
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel